Els Vercammen

2.2k total citations · 2 hit papers
26 papers, 1.6k citations indexed

About

Els Vercammen is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Els Vercammen has authored 26 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 7 papers in Cardiology and Cardiovascular Medicine and 5 papers in Genetics. Recurrent topics in Els Vercammen's work include Erythropoietin and Anemia Treatment (13 papers), Hemoglobinopathies and Related Disorders (5 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Els Vercammen is often cited by papers focused on Erythropoietin and Anemia Treatment (13 papers), Hemoglobinopathies and Related Disorders (5 papers) and Antiplatelet Therapy and Cardiovascular Diseases (4 papers). Els Vercammen collaborates with scholars based in Belgium, United Kingdom and United States. Els Vercammen's co-authors include Bernardo L. Rapoport, Timothy J. Littlewood, J.W.R. Nortier, Emilio Bajetta, Marek Pawlicki, George Manikhas, M. Biakhov, Anton Roth, David Dodwell and Brian Leyland‐Jones and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Els Vercammen

24 papers receiving 1.6k citations

Hit Papers

Effects of Epoetin Alfa on Hematologic Parameters and Qua... 2001 2026 2009 2017 2001 2005 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
    2001 792 citations Timothy J. Littlewood, Emilio Bajetta et al. Journal of Clinical Oncology profile →
  2. Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study
    2005 505 citations Brian Leyland‐Jones, Semiglazov Vf et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Els Vercammen Belgium 10 1.3k 433 337 305 166 26 1.6k
Brenda Sarokhan United States 10 953 0.7× 286 0.7× 214 0.6× 254 0.8× 165 1.0× 11 1.2k
David H. Regan United States 7 774 0.6× 252 0.6× 196 0.6× 263 0.9× 97 0.6× 9 991
Stanley E. Gräber United States 18 1.1k 0.9× 151 0.3× 164 0.5× 364 1.2× 138 0.8× 42 1.7k
Hans-Ulrich Burger Switzerland 9 1.4k 1.1× 122 0.3× 198 0.6× 445 1.5× 51 0.3× 14 1.8k
Iain C. Macdougall United Kingdom 18 862 0.7× 58 0.1× 96 0.3× 331 1.1× 93 0.6× 32 1.1k
Tim Littlewood United Kingdom 23 1.3k 1.0× 345 0.8× 94 0.3× 582 1.9× 75 0.5× 62 1.8k
Raúl G. Carlini Venezuela 17 436 0.3× 347 0.8× 29 0.1× 123 0.4× 236 1.4× 31 1.4k
Marianna Politou Greece 23 1.7k 1.3× 721 1.7× 57 0.2× 845 2.8× 63 0.4× 48 2.4k
Philip W. Friederich Netherlands 19 1.2k 1.0× 156 0.4× 114 0.3× 245 0.8× 88 0.5× 23 2.0k
Steven A. Gould United States 20 208 0.2× 27 0.1× 522 1.5× 228 0.7× 214 1.3× 48 1.9k

Countries citing papers authored by Els Vercammen

Since Specialization
Citations

This map shows the geographic impact of Els Vercammen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Els Vercammen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Els Vercammen more than expected).

Fields of papers citing papers by Els Vercammen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Els Vercammen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Els Vercammen. The network helps show where Els Vercammen may publish in the future.

Co-authorship network of co-authors of Els Vercammen

This figure shows the co-authorship network connecting the top 25 collaborators of Els Vercammen. A scholar is included among the top collaborators of Els Vercammen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Els Vercammen. Els Vercammen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Macdougall, Iain C., Nicole Casadevall, Francesco Locatelli, et al.. (2014). Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrology Dialysis Transplantation. 30(3). 451–460. 52 indexed citations
2.
Schipperus, Martin R., et al.. (2010). Hepcidin Levels and Erythropoietin Alfa Resistance In Patients with Chemotherapy Induced Anemia (CIA). Blood. 116(21). 3216–3216.
3.
Vincent, Jean‐Louis, Herbert Spapen, Jacques Créteur, et al.. (2006). Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: Results of a randomized, double-blind, placebo-controlled trial*. Critical Care Medicine. 34(6). 1661–1667. 27 indexed citations
4.
Chakraborty, Abhijit, Jaya Natarajan, Mary Guilfoyle, et al.. (2005). Population Pharmacokinetics of Erythropoietin in Critically Ill Subjects. The Journal of Clinical Pharmacology. 45(2). 193–202. 9 indexed citations
5.
Dicato, M., et al.. (2005). The relationship of body weight and efficacy of fixed dose epoetin alfa vs placebo. Journal of Clinical Oncology. 23(16_suppl). 8192–8192. 4 indexed citations
6.
Leyland‐Jones, Brian, Semiglazov Vf, Marek Pawlicki, et al.. (2005). Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study. Journal of Clinical Oncology. 23(25). 5960–5972. 505 indexed citations breakdown →
7.
Vercammen, Els, et al.. (2005). Analysis of the effect of body weight on the efficacy and safety of epoetin alfa. Journal of Clinical Oncology. 23(16_suppl). 8184–8184. 1 indexed citations
8.
Littlewood, Timothy J., J.W.R. Nortier, Bernardo L. Rapoport, et al.. (2003). Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non‐platinum chemotherapy. Hematological Oncology. 21(4). 169–180. 33 indexed citations
9.
Littlewood, Timothy J., et al.. (2001). Effects of Epoetin Alfa on Hematologic Parameters and Quality of Life in Cancer Patients Receiving Nonplatinum Chemotherapy: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology. 19(11). 2865–2874. 792 indexed citations breakdown →
10.
Vercammen, Els, et al.. (2001). Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo‐controlled trial. Transfusion. 41(7). 957–963. 42 indexed citations
11.
Chang, Chia‐Hsien, Brian W. Bresnahan, Martin Zagari, et al.. (1999). Cross-language validation of the Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire. European Journal of Cancer. 35. S359–S359. 7 indexed citations
12.
Hecken, Anne Van, Marleen Depré, Jozef Arnout, et al.. (1998). Pharmacodynamics and pharmacokinetics of RWJ-53308, a nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist, in healthy men. Naunyn-Schmiedeberg s Archives of Pharmacology. 358(1). 1 indexed citations
13.
14.
Paolasso, Ernesto, et al.. (1992). The ridogrel versus aspirin patency trial (rapt). Circulation. 86(4). 642–642. 16 indexed citations
15.
Weber, Christian, Johan Beetens, F. Tegtmeier, et al.. (1992). Ridogrel Inhibits Systemic and Renal Formation of Thromboxane A2 and Antagonizes Platelet Thromboxane A2/Prostaglandin Endoperoxide Receptors upon Chronic Administration to Man. Thrombosis and Haemostasis. 68(2). 214–220. 4 indexed citations
16.
Werf, Frans Van de, et al.. (1991). Pilot-study of combined administration of ridogrel and alteplase in patients with acute myocardial-infarction. Coronary Artery Disease. 2(4). 455–463. 4 indexed citations
17.
Timmermans, Carl, Matty Vrolix, Johan Vanhaecke, et al.. (1991). Ridogrel in the setting of percutaneous transluminal coronary angioplasty. The American Journal of Cardiology. 68(5). 463–466. 13 indexed citations
18.
Rapold, Hans J., et al.. (1991). Pilot study of combined administration of ridogrel and rt-PA in patients with acute myocardial infarction (AMI). Journal of the American College of Cardiology. 17(2). A114–A114. 2 indexed citations
19.
Hoeyweghen, R. Van, Els Vercammen, & Leo Bossaert. (1989). Tolerance and pharmacokinetics of flunarizine after cardiac arrest. Resuscitation. 17. S111–S119. 1 indexed citations
20.
Clerck, Fred De, Johan Beetens, A. Van de Water, Els Vercammen, & Paul A. J. Janssen. (1989). R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - II. Pharmacological Effects In Vivo and Ex Vivo. Thrombosis and Haemostasis. 61(1). 43–49. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brenda Sarokhan Breakdown of academic impact, for papers by David H. Regan Breakdown of academic impact, for papers by Stanley E. Gräber Breakdown of academic impact, for papers by Hans-Ulrich Burger Breakdown of academic impact, for papers by Iain C. Macdougall Breakdown of academic impact, for papers by Tim Littlewood Breakdown of academic impact, for papers by Raúl G. Carlini Breakdown of academic impact, for papers by Marianna Politou Breakdown of academic impact, for papers by Philip W. Friederich Breakdown of academic impact, for papers by Steven A. Gould
Rankless by CCL
2026